Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13040294 | 0.98 | LTA4H (0.32) | LTA4HITGB1ITGA2VNN1 | |
| SCHEMBL13040295 | 0.98 | PAX8 (0.31) | LTA4HITGB1ITGA2ARMEN1 | |
| SCHEMBL13040293 | 0.94 | BTK (0.33) | VNN1 | |
| SCHEMBL13040276 | 0.74 | KRAS (0.41) | — | |
| SCHEMBL31207649 | 0.73 | NOTUM (0.36) | ARMEN1NPC1RAB9AKMT2A | |
| SCHEMBL13040302 | 0.73 | BRD4 (0.38) | ITGB1ITGA2 | |
| SCHEMBL13040274 | 0.71 | KRAS (0.39) | — | |
| SCHEMBL13040273 | 0.71 | KRAS (0.42) | — | |
| SCHEMBL12443431 | 0.70 | HSD11B1 (0.35) | LTA4HARMEN1NPC1RAB9A | |
| SCHEMBL25907140 | 0.69 | LTA4H (0.38) | LTA4HVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-04 | — | — | US | disclosed |
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-04 | — | — | US | disclosed |
| WO-2010127088-A2 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | APOBEC3G, HYOU1, HTR3C | LTA4H 642/4885ITGB1 2698/4885ITGA2 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.